Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis.

Clarke JD, Dzierlenga AL, Nelson NR, Li H, Werts S, Goedken MJ, Cherrington NJ.

Diabetes. 2015 Sep;64(9):3305-13. doi: 10.2337/db14-1947. Epub 2015 May 27.

2.

Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis.

Canet MJ, Hardwick RN, Lake AD, Dzierlenga AL, Clarke JD, Goedken MJ, Cherrington NJ.

Drug Metab Dispos. 2015 Feb;43(2):266-72. doi: 10.1124/dmd.114.060574. Epub 2014 Dec 8.

3.

Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models.

Canet MJ, Hardwick RN, Lake AD, Dzierlenga AL, Clarke JD, Cherrington NJ.

Drug Metab Dispos. 2014 Apr;42(4):586-95. doi: 10.1124/dmd.113.055996. Epub 2014 Jan 2.

4.
5.

Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin.

Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM, Whitington PF.

Am J Physiol Gastrointest Liver Physiol. 2004 Nov;287(5):G1035-43. Epub 2004 Jul 15.

6.

Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.

Higgins JW, Bedwell DW, Zamek-Gliszczynski MJ.

Drug Metab Dispos. 2012 Jun;40(6):1170-7. doi: 10.1124/dmd.112.044875. Epub 2012 Mar 9.

7.

The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation.

Chung HK, Kim YK, Park JH, Ryu MJ, Chang JY, Hwang JH, Lee CH, Kim SH, Kim HJ, Kweon GR, Kim KS, Shong M.

Liver Int. 2015 Apr;35(4):1341-53. doi: 10.1111/liv.12741. Epub 2015 Jan 10.

PMID:
25443620
8.

The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.

Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, Sabolić I, Koepsell H, Brockmöller J.

Clin Pharmacol Ther. 2009 Sep;86(3):299-306. doi: 10.1038/clpt.2009.92. Epub 2009 Jun 17.

PMID:
19536068
9.

Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet.

Ding Y, Sun X, Chen Y, Deng Y, Qian K.

Eur J Pharmacol. 2015 Aug 15;761:405-12. doi: 10.1016/j.ejphar.2015.05.005. Epub 2015 May 9.

PMID:
25967348
10.

Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.

Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, Zanger UM, Keppler D, Schwab M, Schaeffeler E.

Hepatology. 2009 Oct;50(4):1227-40. doi: 10.1002/hep.23103.

PMID:
19591196
11.

Synergistic interaction between genetics and disease on pravastatin disposition.

Clarke JD, Hardwick RN, Lake AD, Lickteig AJ, Goedken MJ, Klaassen CD, Cherrington NJ.

J Hepatol. 2014 Jul;61(1):139-47. doi: 10.1016/j.jhep.2014.02.021. Epub 2014 Mar 5.

12.

MicroRNA profiles following metformin treatment in a mouse model of non-alcoholic steatohepatitis.

Katsura A, Morishita A, Iwama H, Tani J, Sakamoto T, Tatsuta M, Toyota Y, Fujita K, Kato K, Maeda E, Nomura T, Miyoshi H, Yoneyama H, Himoto T, Fujiwara S, Kobara H, Mori H, Niki T, Ono M, Hirashima M, Masaki T.

Int J Mol Med. 2015 Apr;35(4):877-84. doi: 10.3892/ijmm.2015.2092. Epub 2015 Feb 6.

13.

Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1.

Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K.

Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.

14.

Role of ADAMTS13 in diet-induced liver steatosis.

Geys L, Roose E, Vanhoorelbeke K, Bedossa P, Scroyen I, Lijnen HR.

Mol Med Rep. 2017 Aug;16(2):1451-1458. doi: 10.3892/mmr.2017.6714. Epub 2017 Jun 7.

PMID:
29067443
15.

Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants.

Cho SK, Yoon JS, Lee MG, Lee DH, Lim LA, Park K, Park MS, Chung JY.

Clin Pharmacol Ther. 2011 Mar;89(3):416-21. doi: 10.1038/clpt.2010.266. Epub 2011 Jan 26.

PMID:
21270793
16.
17.

Over-expressing the soluble gp130-Fc does not ameliorate methionine and choline deficient diet-induced non alcoholic steatohepatitis in mice.

Kammoun HL, Allen TL, Henstridge DC, Kraakman MJ, Peijs L, Rose-John S, Febbraio MA.

PLoS One. 2017 Jun 20;12(6):e0179099. doi: 10.1371/journal.pone.0179099. eCollection 2017.

18.

Effects of Nonalcoholic Fatty Liver Disease on Hepatic CYP2B1 and in Vivo Bupropion Disposition in Rats Fed a High-Fat or Methionine/Choline-Deficient Diet.

Cho SJ, Kim SB, Cho HJ, Chong S, Chung SJ, Kang IM, Lee JI, Yoon IS, Kim DD.

J Agric Food Chem. 2016 Jul 13;64(27):5598-606. doi: 10.1021/acs.jafc.6b01663. Epub 2016 Jun 29.

PMID:
27321734
19.

Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure.

Komazawa H, Yamaguchi H, Hidaka K, Ogura J, Kobayashi M, Iseki K.

J Pharm Sci. 2013 Mar;102(3):1086-94. doi: 10.1002/jps.23433. Epub 2012 Dec 29.

PMID:
23280877
20.

Hepatoprotective Effect and Synergism of Bisdemethoycurcumin against MCD Diet-Induced Nonalcoholic Fatty Liver Disease in Mice.

Kim SB, Kang OH, Lee YS, Han SH, Ahn YS, Cha SW, Seo YS, Kong R, Kwon DY.

PLoS One. 2016 Feb 16;11(2):e0147745. doi: 10.1371/journal.pone.0147745. eCollection 2016.

Supplemental Content

Support Center